Matthew A Lewis, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lewis’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A131557 · Current
Licensed to practise in California · since 2014 · expires 2028-07-31 · George Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$87,960
Medicare paid this office $87,960 for 421 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 237 | $30,017 | $87 |
| Long return visit (40+ min) | 112 | $29,370 | $150 |
| Destruction of precancer skin growth, 1 growth | 70 | $5,078 | $50 |
| New patient visit (45+ min) | 40 | $4,554 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $3,190 | $103 |
See all 12 services
| Return visit (30+ min) | 237 | $30,017 | $87 |
| Long return visit (40+ min) | 112 | $29,370 | $150 |
| Destruction of precancer skin growth, 1 growth | 70 | $5,078 | $50 |
| New patient visit (45+ min) | 40 | $4,554 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $3,190 | $103 |
| Short return visit (20+ min) | 53 | $3,028 | $47 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,985 | $117 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 86 | $1,499 | $15 |
| New patient visit (30+ min) | 23 | $1,445 | $63 |
| Biopsy of related skin growth, first growth | 43 | $1,309 | $27 |
| Destruction of precancer skin growth, 2-14 growths | 51 | $569 | $2 |
| Biopsy of related skin growth, each additional growth | 14 | $396 | $20 |
Procedures Medicare counted
| Removal of skin lesions | 199 | More than 79% of doctors who do this |
| Skin biopsy | 99 | More than 76% of doctors who do this |
Who their Medicare patients are
421 Original Medicare patients in 2024. Average age 72 · Under 65 13% · 85 and older 8% · Women 56% · Also on Medicaid 23% · Health risk score 1.60. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 65% · Diabetes 25% · Coronary heart disease 25% · Chronic kidney disease 23% · Depression 21% · Atrial fibrillation 19% · Heart failure 16% · Cancer 15% · COPD 11% · Dementia 9% · Stroke 8%.
The office billed $397,412, Medicare allowed $118,323 and paid $87,960; for 1,397 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 421 | 1,397 | 72 | 1.60 | $397,412 | $87,960 |
| 2023 | 450 | 1,335 | 71 | 1.59 | $368,150 | $73,564 |
| 2022 | 350 | 1,058 | 71 | 1.41 | $290,577 | $54,712 |
| 2021 | 380 | 1,213 | 71 | 1.44 | $348,368 | $68,094 |
| 2020 | 388 | 1,329 | 71 | 1.54 | $266,148 | $53,220 |
| 2019 | 394 | 1,252 | 71 | 1.40 | $150,605 | $53,391 |
| 2018 | 461 | 1,440 | 72 | 1.47 | $160,847 | $59,121 |
| 2017 | 456 | 1,309 | 70 | 1.41 | $189,105 | $62,718 |
| 2016 | 353 | 916 | 71 | 1.42 | $164,172 | $50,987 |
| 2015 | 112 | 284 | 70 | 1.17 | $45,599 | $13,653 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Return visit (30+ min) | 225 | $29,555 | $81 |
| Long return visit (40+ min) | 37 | $8,766 | $125 |
| Short return visit (20+ min) | 93 | $6,009 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $5,375 | $110 |
| New patient visit (45+ min) | 40 | $4,542 | $114 |
| Destruction of precancer skin growth, 1 growth | 71 | $4,036 | $47 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,468 | $120 |
| New patient visit (30+ min) | 44 | $2,613 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,386 | $69 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 18 | $1,361 | $76 |
| Biopsy of related skin growth, first growth | 43 | $1,232 | $26 |
| Destruction of precancer skin growth, 2-14 growths | 56 | $631 | $2 |
| Biopsy of related skin growth, each additional growth | 15 | $398 | $20 |
2022: 11 services
| Return visit (30+ min) | 192 | $28,284 | $79 |
| Short return visit (20+ min) | 130 | $8,109 | $49 |
| New patient visit (45+ min) | 34 | $3,700 | $109 |
| Long return visit (40+ min) | 14 | $3,500 | $117 |
| Destruction of precancer skin growth, 1 growth | 55 | $3,099 | $44 |
| New patient visit (30+ min) | 36 | $2,171 | $60 |
| Biopsy of related skin growth, first growth | 42 | $1,160 | $25 |
| Destruction of skin growth, 1-14 growths | 12 | $713 | $55 |
| Punch biopsy, first skin growth | 12 | $465 | $39 |
| Destruction of precancer skin growth, 2-14 growths | 42 | $418 | $2 |
| Biopsy of related skin growth, each additional growth | 12 | $338 | $17 |
2021: 10 services
| Return visit (30+ min) | 205 | $34,601 | $84 |
| Short return visit (20+ min) | 143 | $9,672 | $53 |
| Long return visit (40+ min) | 21 | $5,389 | $122 |
| New patient visit (45+ min) | 44 | $4,989 | $113 |
| Destruction of precancer skin growth, 1 growth | 63 | $3,230 | $44 |
| New patient visit (30+ min) | 39 | $2,683 | $69 |
| Biopsy of related skin growth, first growth | 51 | $1,619 | $25 |
| Destruction of skin growth, 1-14 growths | 13 | $977 | $57 |
| Biopsy of related skin growth, each additional growth | 19 | $589 | $20 |
| Destruction of precancer skin growth, 2-14 growths | 54 | $426 | $2 |
2020: 14 services
| Return visit (30+ min) | 150 | $21,882 | $68 |
| Short return visit (20+ min) | 183 | $10,761 | $42 |
| Destruction of precancer skin growth, 1 growth | 74 | $4,360 | $49 |
| New patient visit (30+ min) | 51 | $3,393 | $67 |
| New patient visit (45+ min) | 23 | $2,536 | $110 |
| Long return visit (40+ min) | 14 | $1,943 | $93 |
| Biopsy of related skin growth, first growth | 55 | $1,620 | $27 |
| Destruction of skin growth, 1-14 growths | 13 | $937 | $59 |
| New patient visit (15+ min) | 18 | $858 | $48 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $683 | $40 |
| Destruction of precancer skin growth, 2-14 growths | 65 | $677 | $2 |
| Injection into skin growth, 1-7 growths | 12 | $527 | $28 |
| Biopsy of related skin growth, each additional growth | 17 | $456 | $22 |
| Telehealth originating site facility fee | 15 | $341 | $21 |
2019: 13 services
| Return visit (30+ min) | 142 | $17,354 | $66 |
| Short return visit (20+ min) | 173 | $9,792 | $41 |
| New patient visit (45+ min) | 54 | $5,947 | $110 |
| Long return visit (40+ min) | 28 | $4,689 | $96 |
| Destruction of precancer skin growth, 1 growth | 80 | $4,327 | $46 |
| New patient visit (30+ min) | 59 | $3,416 | $58 |
| Biopsy of related skin growth, first growth | 51 | $1,408 | $27 |
| Punch biopsy, first skin growth | 20 | $1,052 | $44 |
| Destruction of skin growth, 1-14 growths | 11 | $791 | $61 |
| Destruction of precancer skin growth, 2-14 growths | 69 | $585 | $2 |
| Biopsy of related skin growth, each additional growth | 20 | $447 | $19 |
| Injection into skin growth, 1-7 growths | 12 | $414 | $28 |
| New patient visit (15+ min) | 13 | $388 | $30 |
2018: 11 services
| Return visit (30+ min) | 173 | $17,665 | $64 |
| Short return visit (20+ min) | 165 | $8,615 | $43 |
| Long return visit (40+ min) | 41 | $6,459 | $87 |
| New patient visit (30+ min) | 87 | $5,060 | $58 |
| New patient visit (45+ min) | 48 | $5,001 | $104 |
| Destruction of precancer skin growth, 1 growth | 96 | $4,369 | $40 |
| Biopsy of single growth of skin and/or tissue | 76 | $2,865 | $35 |
| Destruction of skin growth, 1-14 growths | 31 | $2,152 | $58 |
| Destruction of precancer skin growth, 2-14 growths | 72 | $815 | $2 |
| Biopsy of each additional growth of skin and/or tissue | 23 | $655 | $22 |
| Injection into skin growth, 1-7 growths | 15 | $537 | $22 |
2017: 10 services
| Return visit (30+ min) | 162 | $17,572 | $64 |
| Long return visit (40+ min) | 59 | $10,693 | $94 |
| New patient visit (45+ min) | 71 | $7,721 | $109 |
| Short return visit (20+ min) | 140 | $6,778 | $41 |
| New patient visit (30+ min) | 94 | $5,482 | $58 |
| Destruction of precancer skin growth, 1 growth | 71 | $3,570 | $43 |
| Biopsy of single growth of skin and/or tissue | 74 | $2,660 | $33 |
| Destruction of skin growth, 1-14 growths | 21 | $1,571 | $63 |
| Biopsy of each additional growth of skin and/or tissue | 26 | $725 | $20 |
| Destruction of precancer skin growth, 2-14 growths | 54 | $552 | $2 |
2016: 10 services
| Long return visit (40+ min) | 66 | $12,718 | $98 |
| Return visit (30+ min) | 104 | $9,711 | $66 |
| New patient visit (30+ min) | 94 | $5,592 | $59 |
| New patient visit (45+ min) | 49 | $5,316 | $108 |
| Short return visit (20+ min) | 92 | $4,882 | $43 |
| New patient visit (60+ min) | 30 | $4,413 | $147 |
| Biopsy of single growth of skin and/or tissue | 70 | $2,930 | $37 |
| Destruction of precancer skin growth, 1 growth | 51 | $2,668 | $45 |
| Biopsy of each additional growth of skin and/or tissue | 22 | $750 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 37 | $302 | $2 |
2015: 8 services
| New patient visit (30+ min) | 43 | $2,736 | $64 |
| New patient visit (45+ min) | 21 | $2,432 | $116 |
| Short return visit (20+ min) | 34 | $1,597 | $46 |
| Return visit (30+ min) | 13 | $1,406 | $70 |
| Destruction of precancer skin growth, 1 growth | 18 | $991 | $50 |
| Biopsy of single growth of skin and/or tissue | 19 | $730 | $38 |
| Short return visit (20+ min) | 12 | $476 | $40 |
| Destruction of precancer skin growth, 2-14 growths | 14 | $90 | $2 |
Medicaid work
$12,528 in 2024
Medicaid paid $12,528 for 155 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 69 | $6,453 |
| Return visit (30+ min) | 86 | $6,075 |
| 2024 | 155 | 2 | 22 | $12,528 |
| 2023 | 251 | 1 | 28 | $9,819 |
| 2022 | 261 | 1 | 31 | $9,944 |
| 2021 | 254 | 1 | 29 | $8,727 |
| 2020 | 268 | 2 | 23 | $8,108 |
| 2019 | 250 | 2 | 22 | $8,661 |
| 2018 | 279 | 2 | 25 | $10,022 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 251 | $9,819 |
2022
| Return visit (30+ min) | 261 | $9,944 |
2021
| Return visit (30+ min) | 254 | $8,727 |
2020
| Return visit (30+ min) | 171 | $5,924 |
| Short return visit (20+ min) | 97 | $2,184 |
2019
| Return visit (30+ min) | 176 | $6,720 |
| Short return visit (20+ min) | 74 | $1,941 |
2018
| Return visit (30+ min) | 205 | $8,141 |
| Short return visit (20+ min) | 74 | $1,882 |
Drugs they prescribed that Part D paid
$3,893,282
Pharmacies billed $3,893,282 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (46 of 1,862) in 2024. A higher opioid share than 9 in 10 peers; the typical dermatology clinician is at 0%.
1,238 generic and fewer than 11 brand-name prescriptions · $3,893,282 in drug cost · 96 antibiotic prescriptions to 31 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | None | 130 | $563,923 | $4,338 |
| Dupixent | None | 142 | $526,103 | $3,705 |
| Privigen | Immune globulin | 36 | $454,012 | $12,611 |
| Taltz | None | 46 | $372,813 | $8,105 |
| Gamunex-C | Immune globulin | 27 | $338,663 | $12,543 |
See all 52 drugs
| Dupixent | None | 130 | $563,923 | $4,338 |
| Dupixent | None | 142 | $526,103 | $3,705 |
| Privigen | Immune globulin | 36 | $454,012 | $12,611 |
| Taltz | None | 46 | $372,813 | $8,105 |
| Gamunex-C | Immune globulin | 27 | $338,663 | $12,543 |
| Skyrizi | None | 15 | $301,888 | $20,126 |
| Bimzelx | None | 21 | $281,558 | $13,408 |
| Skyrizi | None | 13 | $247,252 | $19,019 |
| Rinvoq | None | 19 | $135,074 | $7,109 |
| Cosentyx (2 Syringes) | None | 15 | $99,587 | $6,639 |
| Humira(Cf) | None | 14 | $96,257 | $6,876 |
| Xeljanz | None | 14 | $72,674 | $5,191 |
| Otezla | None | 11 | $49,917 | $4,538 |
| Mycophenolate Mofetil | None | 44 | $25,771 | $586 |
| Qbrexza | None | 16 | $10,124 | $633 |
| Calcipotriene | None | 27 | $6,740 | $250 |
| Clobetasol Propionate | None | 52 | $4,102 | $79 |
| Fluocinonide | None | 63 | $2,706 | $43 |
| Tretinoin | None | 26 | $2,070 | $80 |
| Triamcinolone Acetonide | None | 88 | $2,064 | $23 |
| Clindamycin Phosphate | None | 33 | $1,752 | $53 |
| Doxycycline Hyclate | None | 41 | $1,597 | $39 |
| Mycophenolic Acid | None | 14 | $1,512 | $108 |
| Desonide | None | 15 | $1,498 | $100 |
| Metronidazole | None | 14 | $1,219 | $87 |
| Hydroxychloroquine Sulfate | None | 40 | $1,130 | $28 |
| Ketoconazole | None | 60 | $1,023 | $17 |
| Fluorouracil | None | 13 | $1,011 | $78 |
| Betamethasone Diprop Augmented | None | 24 | $936 | $39 |
| Minoxidil | None | 67 | $866 | $13 |
| Dexamethasone | None | 18 | $816 | $45 |
| Ivermectin | None | 21 | $799 | $38 |
| Cefuroxime | None | 13 | $780 | $60 |
| Pregabalin | None | 11 | $687 | $62 |
| Prednisone | None | 63 | $548 | $9 |
| Ciclopirox | None | 13 | $398 | $31 |
| Nystatin | None | 14 | $363 | $26 |
| Mometasone Furoate | None | 11 | $359 | $33 |
| Hydrocodone-Acetaminophen | None | 17 | $330 | $19 |
| Oxycodone-Acetaminophen | None | 21 | $324 | $15 |
| Rosuvastatin | None | 12 | $312 | $26 |
| Hydroxyzine | None | 19 | $285 | $15 |
| Gabapentin | None | 21 | $276 | $13 |
| Cilostazol | None | 12 | $239 | $20 |
| Mupirocin | None | 24 | $213 | $9 |
| Hydrocortisone | None | 36 | $190 | $5 |
| Sulfamethoxazole-Trimethoprim | None | 11 | $170 | $15 |
| Finasteride | None | 13 | $97 | $7 |
| Metoprolol | None | 11 | $84 | $8 |
| Methotrexate | None | 13 | $49 | $4 |
| Zolpidem | None | 14 | $37 | $3 |
| Alendronate | None | 11 | $24 | $2 |
Year by year
| 2024 | 1,862 | 278 | 3% (46) | None | $3,893,282 |
| 2023 | 1,913 | 278 | 2% (44) | None | $3,804,245 |
| 2022 | 1,960 | 266 | 2% (46) | None | $3,835,657 |
| 2021 | 1,883 | 303 | 3% (60) | 23% | $3,227,596 |
| 2020 | 1,843 | 302 | 3% (51) | None | $2,672,121 |
| 2019 | 1,444 | 249 | 3% (39) | None | $1,677,246 |
| 2018 | 1,655 | 300 | 1% (16) | 23% | $1,911,603 |
| 2017 | 1,641 | 304 | None | None | $1,211,760 |
| 2016 | 945 | 230 | None | None | $619,890 |
| 2015 | 169 | 76 | 0% (0) | 17% | $62,623 |
| 2014 | 515 | 159 | 0% (0) | None | $278,360 |
| 2013 | 557 | 180 | 0% (0) | 17% | $99,298 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 47 drugs
| Skyrizi | None | 24 | $484,419 | $20,184 |
| Dupixent | None | 130 | $481,006 | $3,700 |
| Privigen | Immune globulin | 12 | $312,158 | $26,013 |
| Skyrizi | None | 13 | $277,487 | $21,345 |
| Taltz | None | 39 | $277,429 | $7,114 |
| Dupixent | None | 69 | $263,714 | $3,822 |
| Humira | None | 20 | $219,861 | $10,993 |
| Gammaplex | Immune globulin | 14 | $202,132 | $14,438 |
| Cimzia | None | 12 | $185,092 | $15,424 |
| Gamunex-C | Immune globulin | 13 | $179,822 | $13,832 |
| Gammagard Liquid | Immune globulin | 24 | $170,219 | $7,092 |
| Cosentyx (2 Syringes) | None | 12 | $92,237 | $7,686 |
| Xeljanz | None | 15 | $91,962 | $6,131 |
| Humira(Cf) | None | 13 | $89,382 | $6,876 |
| Mycophenolate Mofetil | None | 57 | $15,241 | $267 |
| Sildenafil Citrate | None | 22 | $8,829 | $401 |
| Calcipotriene | None | 20 | $6,163 | $308 |
| Fluocinonide | None | 82 | $5,123 | $62 |
| Clobetasol Propionate | None | 40 | $4,696 | $117 |
| Tretinoin | None | 36 | $4,487 | $125 |
| Desonide | None | 18 | $3,190 | $177 |
| Clindamycin Phosphate | None | 22 | $2,898 | $132 |
| Doxycycline Hyclate | None | 65 | $2,730 | $42 |
| Ivermectin | None | 19 | $2,666 | $140 |
| Metronidazole | None | 26 | $2,544 | $98 |
| Ketoconazole | None | 83 | $2,233 | $27 |
| Betamethasone Diprop Augmented | None | 44 | $2,141 | $49 |
| Hydroxychloroquine Sulfate | None | 59 | $1,902 | $32 |
| Cefuroxime | None | 18 | $1,322 | $73 |
| Triamcinolone Acetonide | None | 73 | $1,276 | $17 |
| Fluorouracil | None | 13 | $1,190 | $92 |
| Minoxidil | None | 65 | $1,178 | $18 |
| Prednisone | None | 100 | $1,088 | $11 |
| Ciclopirox | None | 21 | $994 | $47 |
| Pregabalin | None | 16 | $920 | $57 |
| Dexamethasone | None | 18 | $626 | $35 |
| Hydrocodone-Acetaminophen | None | 23 | $575 | $25 |
| Gabapentin | None | 38 | $574 | $15 |
| Mupirocin | None | 40 | $503 | $13 |
| Hydroxyzine | None | 22 | $497 | $23 |
| Valacyclovir | None | 14 | $480 | $34 |
| Ammonium Lactate | None | 17 | $470 | $28 |
| Amitriptyline | None | 18 | $451 | $25 |
| Oxycodone-Acetaminophen | None | 15 | $387 | $26 |
| Pentoxifylline | None | 12 | $368 | $31 |
| Methotrexate | None | 22 | $360 | $16 |
| Hydrocortisone | None | 32 | $329 | $10 |
2022: 50 drugs
| Skyrizi | None | 33 | $635,281 | $19,251 |
| Dupixent | None | 142 | $503,862 | $3,548 |
| Humira | None | 27 | $262,999 | $9,741 |
| Gamunex-C | Immune globulin | 26 | $262,225 | $10,086 |
| Cosentyx Pen (2 Pens) | None | 25 | $241,618 | $9,665 |
| Gammagard Liquid | Immune globulin | 40 | $239,927 | $5,998 |
| Taltz | None | 34 | $230,349 | $6,775 |
| Dupixent | None | 52 | $189,821 | $3,650 |
| Humira(Cf) | None | 21 | $153,301 | $7,300 |
| Enbrel Mini | None | 19 | $137,377 | $7,230 |
| Rinvoq | None | 14 | $121,227 | $8,659 |
| Mycophenolate Mofetil | None | 45 | $12,387 | $275 |
| Clobetasol Propionate | None | 54 | $7,794 | $144 |
| Tetracycline | None | 11 | $7,681 | $698 |
| Sildenafil Citrate | None | 21 | $7,558 | $360 |
| Doxycycline Hyclate | None | 102 | $5,810 | $57 |
| Fluocinonide | None | 71 | $5,233 | $74 |
| Cefuroxime | None | 22 | $4,079 | $185 |
| Betamethasone Dipropionate | None | 20 | $3,772 | $189 |
| Mycophenolic Acid | None | 13 | $3,415 | $263 |
| Ketoconazole | None | 101 | $3,018 | $30 |
| Trexall | None | 12 | $2,607 | $217 |
| Hydroxychloroquine Sulfate | None | 55 | $2,118 | $39 |
| Tretinoin | None | 15 | $2,101 | $140 |
| Metronidazole | None | 18 | $2,048 | $114 |
| Triamcinolone Acetonide | None | 98 | $1,842 | $19 |
| Halobetasol Propionate | None | 13 | $1,792 | $138 |
| Betamethasone Diprop Augmented | None | 29 | $1,744 | $60 |
| Clindamycin Phosphate | None | 20 | $1,317 | $66 |
| Fluorouracil | None | 11 | $1,232 | $112 |
| Fluocinolone Acetonide | None | 12 | $1,042 | $87 |
| Clotrimazole | None | 13 | $993 | $76 |
| Prednisone | None | 73 | $803 | $11 |
| Valacyclovir | None | 17 | $721 | $42 |
| Hydroxyzine | None | 44 | $687 | $16 |
| Mometasone Furoate | None | 11 | $637 | $58 |
| Mupirocin | None | 41 | $544 | $13 |
| Ammonium Lactate | None | 13 | $492 | $38 |
| Oxycodone-Acetaminophen | None | 20 | $485 | $24 |
| Pentoxifylline | None | 11 | $481 | $44 |
| Terbinafine | None | 19 | $455 | $24 |
| Hydrocortisone | None | 29 | $452 | $16 |
| Diclofenac | None | 14 | $379 | $27 |
| Methotrexate | None | 30 | $358 | $12 |
| Gabapentin | None | 40 | $322 | $8 |
| Pregabalin | None | 12 | $291 | $24 |
| Dexamethasone | None | 15 | $286 | $19 |
| Hydrocodone-Acetaminophen | None | 18 | $233 | $13 |
| Minoxidil | None | 12 | $131 | $11 |
| Sulfamethoxazole-Trimethoprim | None | 11 | $48 | $4 |
2021: 50 drugs
| Dupixent | None | 136 | $448,223 | $3,296 |
| Stelara | None | 16 | $314,751 | $19,672 |
| Skyrizi (2 Syringes) Kit | None | 14 | $232,801 | $16,629 |
| Gammagard Liquid | Immune globulin | 15 | $210,629 | $14,042 |
| Panzyga | Immune globulin | 12 | $210,277 | $17,523 |
| Gamunex-C | Immune globulin | 23 | $198,010 | $8,609 |
| Skyrizi | None | 11 | $196,125 | $17,830 |
| Humira | None | 26 | $193,880 | $7,457 |
| Cosentyx Pen (2 Pens) | None | 17 | $150,924 | $8,878 |
| Thalomid | None | 13 | $143,572 | $11,044 |
| Tremfya | None | 12 | $135,324 | $11,277 |
| Taltz | None | 19 | $132,498 | $6,974 |
| Cosentyx (2 Syringes) | None | 14 | $88,406 | $6,315 |
| Clobetasol Propionate | None | 60 | $5,666 | $94 |
| Mycophenolic Acid | None | 15 | $4,857 | $324 |
| Mycophenolate Mofetil | None | 39 | $4,138 | $106 |
| Betamethasone Diprop Augmented | None | 48 | $4,066 | $85 |
| Halobetasol Propionate | None | 14 | $3,955 | $282 |
| Fluocinonide | None | 68 | $3,916 | $58 |
| Metronidazole | None | 39 | $3,837 | $98 |
| Doxycycline Hyclate | None | 84 | $3,320 | $40 |
| Dapsone | None | 12 | $2,295 | $191 |
| Hydroxychloroquine Sulfate | None | 44 | $2,180 | $50 |
| Triamcinolone Acetonide | None | 119 | $2,087 | $18 |
| Ketoconazole | None | 82 | $2,078 | $25 |
| Prednisone | None | 135 | $1,670 | $12 |
| Clindamycin Phosphate | None | 31 | $1,484 | $48 |
| Fluocinolone Acetonide | None | 15 | $1,241 | $83 |
| Sildenafil Citrate | None | 15 | $1,215 | $81 |
| Pregabalin | None | 19 | $1,121 | $59 |
| Fluorouracil | None | 14 | $1,108 | $79 |
| Methotrexate | None | 22 | $804 | $37 |
| Mometasone Furoate | None | 16 | $645 | $40 |
| Diclofenac | None | 14 | $462 | $33 |
| Valacyclovir | None | 14 | $436 | $31 |
| Hydroxyzine | None | 33 | $400 | $12 |
| Mupirocin | None | 37 | $366 | $10 |
| Gabapentin | None | 32 | $303 | $9 |
| Amitriptyline | None | 11 | $276 | $25 |
| Dexamethasone | None | 12 | $269 | $22 |
| Hydrocodone-Acetaminophen | None | 21 | $267 | $13 |
| Oxycodone-Acetaminophen | None | 15 | $209 | $14 |
| Hydrocortisone | None | 23 | $172 | $7 |
| Minoxidil | None | 12 | $119 | $10 |
| Hydromorphone | None | 12 | $99 | $8 |
| Cephalexin | None | 11 | $98 | $9 |
| Fluconazole | None | 12 | $95 | $8 |
| Azithromycin | None | 11 | $94 | $9 |
| Finasteride | None | 12 | $86 | $7 |
| Ibuprofen | None | 11 | $77 | $7 |
2020: 49 drugs
| Dupixent | None | 111 | $353,126 | $3,181 |
| Privigen | Immune globulin | 12 | $292,140 | $24,345 |
| Skyrizi (2 Syringes) Kit | None | 18 | $291,774 | $16,210 |
| Stelara | None | 15 | $238,529 | $15,902 |
| Panzyga | Immune globulin | 14 | $203,644 | $14,546 |
| Gammagard Liquid | Immune globulin | 15 | $200,392 | $13,359 |
| Enbrel Mini | None | 14 | $150,900 | $10,779 |
| Cosentyx Pen (2 Pens) | None | 22 | $146,490 | $6,659 |
| Taltz | None | 11 | $112,192 | $10,199 |
| Humira | None | 16 | $91,515 | $5,720 |
| Gamunex-C | Immune globulin | 18 | $87,006 | $4,834 |
| Otezla | None | 15 | $50,367 | $3,358 |
| Fluocinonide | None | 104 | $7,349 | $71 |
| Betamethasone Diprop Augmented | None | 77 | $7,105 | $92 |
| Calcipotriene | None | 22 | $5,390 | $245 |
| Clobetasol Propionate | None | 49 | $5,127 | $105 |
| Mycophenolate Mofetil | None | 49 | $4,116 | $84 |
| Dapsone | None | 19 | $3,099 | $163 |
| Doxycycline Hyclate | None | 60 | $2,673 | $45 |
| Clindamycin Phosphate | None | 31 | $2,078 | $67 |
| Triamcinolone Acetonide | None | 122 | $2,068 | $17 |
| Sildenafil Citrate | None | 23 | $1,994 | $87 |
| Halobetasol Propionate | None | 13 | $1,741 | $134 |
| Hydroxychloroquine Sulfate | None | 27 | $1,666 | $62 |
| Metronidazole | None | 23 | $1,629 | $71 |
| Methotrexate | None | 57 | $1,612 | $28 |
| Fluorouracil | None | 12 | $1,423 | $119 |
| Prednisone | None | 112 | $1,380 | $12 |
| Ketoconazole | None | 59 | $1,334 | $23 |
| Tretinoin | None | 12 | $1,307 | $109 |
| Betamethasone Dipropionate | None | 14 | $1,153 | $82 |
| Pregabalin | None | 13 | $848 | $65 |
| Minocycline | None | 18 | $770 | $43 |
| Fluocinolone Acetonide | None | 13 | $765 | $59 |
| Oxycodone-Acetaminophen | None | 24 | $666 | $28 |
| Mometasone Furoate | None | 18 | $592 | $33 |
| Valacyclovir | None | 13 | $515 | $40 |
| Hydroxyzine | None | 26 | $508 | $20 |
| Finasteride | None | 18 | $410 | $23 |
| Mupirocin | None | 45 | $396 | $9 |
| Minoxidil | None | 23 | $322 | $14 |
| Gabapentin | None | 27 | $271 | $10 |
| Terbinafine | None | 22 | $239 | $11 |
| Hydrocodone-Acetaminophen | None | 16 | $225 | $14 |
| Hydrocortisone | None | 25 | $221 | $9 |
| Sulfamethoxazole-Trimethoprim | None | 33 | $221 | $7 |
| Fluconazole | None | 16 | $216 | $13 |
| Diclofenac | None | 11 | $179 | $16 |
| Cilostazol | None | 12 | $121 | $10 |
2019: 36 drugs
| Gammagard Liquid | Immune globulin | 26 | $204,379 | $7,861 |
| Dupixent | None | 65 | $198,437 | $3,053 |
| Taltz | None | 33 | $182,227 | $5,522 |
| Cosentyx | None | 11 | $117,505 | $10,682 |
| Humira(Cf) | None | 15 | $96,384 | $6,426 |
| Cosentyx (2 Syringes) | None | 14 | $90,195 | $6,442 |
| Gamunex-C | Immune globulin | 18 | $85,851 | $4,770 |
| Humira | None | 14 | $74,518 | $5,323 |
| Otezla | None | 12 | $40,431 | $3,369 |
| Fluocinonide | None | 88 | $6,572 | $75 |
| Clobetasol Propionate | None | 69 | $6,439 | $93 |
| Mycophenolate Mofetil | None | 53 | $4,997 | $94 |
| Methotrexate | None | 56 | $3,688 | $66 |
| Calcipotriene | None | 15 | $2,830 | $189 |
| Doxycycline Hyclate | None | 40 | $2,729 | $68 |
| Cyclosporine Modified | None | 11 | $2,617 | $238 |
| Betamethasone Diprop Augmented | None | 23 | $2,281 | $99 |
| Hydroxychloroquine Sulfate | None | 28 | $2,271 | $81 |
| Tretinoin | None | 16 | $2,257 | $141 |
| Betamethasone Dipropionate | None | 13 | $1,970 | $152 |
| Triamcinolone Acetonide | None | 89 | $1,879 | $21 |
| Clindamycin Phosphate | None | 14 | $1,860 | $133 |
| Halobetasol Propionate | None | 13 | $1,541 | $119 |
| Prednisone | None | 108 | $1,198 | $11 |
| Ketoconazole | None | 36 | $976 | $27 |
| Dapsone | None | 11 | $901 | $82 |
| Minocycline | None | 16 | $542 | $34 |
| Oxycodone-Acetaminophen | None | 18 | $500 | $28 |
| Mometasone Furoate | None | 15 | $438 | $29 |
| Hydrocortisone | None | 43 | $398 | $9 |
| Hydroxyzine | None | 15 | $352 | $23 |
| Valacyclovir | None | 14 | $297 | $21 |
| Mupirocin | None | 19 | $243 | $13 |
| Hydrocodone-Acetaminophen | None | 16 | $184 | $12 |
| Sulfamethoxazole-Trimethoprim | None | 32 | $181 | $6 |
| Fluconazole | None | 13 | $102 | $8 |
2018: 40 drugs
| Stelara | None | 14 | $260,862 | $18,633 |
| Dupixent | None | 65 | $201,098 | $3,094 |
| Gammagard Liquid | Immune globulin | 26 | $199,158 | $7,660 |
| Humira | None | 26 | $162,673 | $6,257 |
| Cosentyx Pen (2 Pens) | None | 24 | $133,242 | $5,552 |
| Enbrel | None | 13 | $122,238 | $9,403 |
| Gamunex-C | Immune globulin | 12 | $98,618 | $8,218 |
| Taltz | None | 15 | $97,847 | $6,523 |
| Cosentyx (2 Syringes) | None | 14 | $67,418 | $4,816 |
| Otezla | None | 13 | $63,029 | $4,848 |
| Humira | None | 12 | $59,254 | $4,938 |
| Clobetasol Propionate | None | 88 | $11,962 | $136 |
| Methotrexate | None | 101 | $6,198 | $61 |
| Fluocinonide | None | 65 | $6,023 | $93 |
| Mycophenolate Mofetil | None | 52 | $4,836 | $93 |
| Doxycycline Hyclate | None | 66 | $4,599 | $70 |
| Calcipotriene | None | 18 | $4,595 | $255 |
| Tretinoin | None | 22 | $3,888 | $177 |
| Hydroxychloroquine Sulfate | None | 32 | $3,634 | $114 |
| Betamethasone Diprop Augmented | None | 16 | $2,643 | $165 |
| Triamcinolone Acetonide | None | 124 | $2,383 | $19 |
| Dapsone | None | 24 | $2,324 | $97 |
| Halobetasol Propionate | None | 12 | $2,232 | $186 |
| Prednisone | None | 151 | $2,188 | $14 |
| Clindamycin Phosphate | None | 20 | $2,012 | $101 |
| Fluorouracil | None | 14 | $1,716 | $123 |
| Ketoconazole | None | 47 | $1,632 | $35 |
| Minocycline | None | 21 | $1,303 | $62 |
| Hydroxyzine | None | 23 | $590 | $26 |
| Mupirocin | None | 36 | $552 | $15 |
| Hydrocortisone | None | 48 | $543 | $11 |
| Valacyclovir | None | 19 | $471 | $25 |
| Ammonium Lactate | None | 12 | $272 | $23 |
| Gabapentin | None | 24 | $201 | $8 |
| Terbinafine | None | 25 | $180 | $7 |
| Sulfamethoxazole-Trimethoprim | None | 27 | $146 | $5 |
| Sulfasalazine | None | 12 | $135 | $11 |
| Alendronate | None | 11 | $76 | $7 |
| Cefadroxil | None | 12 | $66 | $6 |
| Ibuprofen | None | 13 | $45 | $3 |
2017: 36 drugs
| Stelara | None | 21 | $365,159 | $17,389 |
| Cosentyx Pen (2 Pens) | None | 31 | $165,803 | $5,348 |
| Humira | None | 26 | $125,316 | $4,820 |
| Gamunex-C | Immune globulin | 11 | $97,492 | $8,863 |
| Gammagard Liquid | Immune globulin | 16 | $93,679 | $5,855 |
| Dupixent | None | 14 | $39,321 | $2,809 |
| Clobetasol Propionate | None | 99 | $24,216 | $245 |
| Fluocinonide | None | 74 | $11,014 | $149 |
| Tacrolimus | None | 13 | $7,468 | $574 |
| Doxycycline Hyclate | None | 94 | $6,649 | $71 |
| Betamethasone Dipropionate | None | 27 | $4,952 | $183 |
| Hydroxychloroquine Sulfate | None | 48 | $4,839 | $101 |
| Methotrexate | None | 82 | $4,485 | $55 |
| Dapsone | None | 25 | $3,609 | $144 |
| Calcipotriene | None | 13 | $3,459 | $266 |
| Tretinoin | None | 18 | $2,935 | $163 |
| Desonide | None | 14 | $2,886 | $206 |
| Clindamycin Phosphate | None | 22 | $2,789 | $127 |
| Prednisone | None | 210 | $2,366 | $11 |
| Triamcinolone Acetonide | None | 93 | $1,940 | $21 |
| Metronidazole | None | 17 | $1,939 | $114 |
| Ketoconazole | None | 46 | $1,783 | $39 |
| Betamethasone Dipropionate | None | 11 | $1,621 | $147 |
| Mycophenolate Mofetil | None | 17 | $1,222 | $72 |
| Hydroxyzine | None | 49 | $1,153 | $24 |
| Ciclopirox | None | 21 | $1,060 | $50 |
| Ivermectin | None | 17 | $700 | $41 |
| Mupirocin | None | 37 | $616 | $17 |
| Minocycline | None | 19 | $587 | $31 |
| Gabapentin | None | 37 | $421 | $11 |
| Mometasone Furoate | None | 14 | $351 | $25 |
| Terbinafine | None | 25 | $318 | $13 |
| Sulfamethoxazole-Trimethoprim | None | 41 | $241 | $6 |
| Fluconazole | None | 14 | $229 | $16 |
| Hydrocortisone | None | 21 | $160 | $8 |
| Finasteride | None | 11 | $131 | $12 |
2016: 21 drugs
| Stelara | 17 | $227,917 | $13,407 |
| Clobetasol Propionate | 100 | $37,834 | $378 |
| Hydroxychloroquine Sulfate | 32 | $4,958 | $155 |
| Doxycycline Hyclate | 41 | $3,471 | $85 |
| Dapsone | 23 | $2,910 | $127 |
| Methotrexate | 65 | $2,878 | $44 |
| Fluocinonide | 22 | $2,787 | $127 |
| Desonide | 17 | $2,486 | $146 |
| Ketoconazole | 20 | $2,141 | $107 |
| Triamcinolone Acetonide | 54 | $1,715 | $32 |
| Prednisone | 122 | $1,455 | $12 |
| Metronidazole | 11 | $1,066 | $97 |
| Mycophenolate Mofetil | 16 | $904 | $56 |
| Ivermectin | 11 | $530 | $48 |
| Mupirocin | 26 | $519 | $20 |
| Valacyclovir | 13 | $442 | $34 |
| Gabapentin | 25 | $416 | $17 |
| Hydroxyzine | 15 | $287 | $19 |
| Nifedical Xl | 13 | $200 | $15 |
| Hydrocortisone | 14 | $154 | $11 |
| Sulfamethoxazole-Trimethoprim | 30 | $141 | $5 |
2015: 3 drugs
| Clobetasol Propionate | 34 | $13,515 | $397 |
| Gabapentin | 17 | $652 | $38 |
| Triamcinolone Acetonide | 18 | $541 | $30 |
2014: 15 drugs
| Humira | 40 | $105,345 | $2,634 |
| Enbrel | 12 | $44,287 | $3,691 |
| Clobetasol Propionate | 57 | $3,718 | $65 |
| Doxycycline Hyclate | 23 | $3,368 | $146 |
| Clindamycin Phosphate | 20 | $1,788 | $89 |
| Triamcinolone Acetonide | 50 | $1,508 | $30 |
| Methotrexate | 24 | $1,470 | $61 |
| Dapsone | 21 | $1,261 | $60 |
| Gabapentin | 21 | $535 | $25 |
| Ammonium Lactate | 12 | $296 | $25 |
| Ketoconazole | 11 | $247 | $22 |
| Hydroxyzine | 12 | $228 | $19 |
| Omeprazole | 14 | $171 | $12 |
| Hydroxychloroquine Sulfate | 12 | $143 | $12 |
| Prednisone | 15 | $133 | $9 |
2013: 13 drugs
| Calcipotriene | 12 | $7,107 | $592 |
| Clobetasol Propionate | 81 | $4,549 | $56 |
| Triamcinolone Acetonide | 82 | $2,608 | $32 |
| Mycophenolate Mofetil | 16 | $2,524 | $158 |
| Desonide | 18 | $2,403 | $134 |
| Doxycycline Hyclate | 13 | $2,399 | $185 |
| Clindamycin Phosphate | 27 | $1,774 | $66 |
| Methotrexate | 31 | $1,415 | $46 |
| Tretinoin | 11 | $771 | $70 |
| Ketoconazole | 21 | $544 | $26 |
| Hydroxyzine | 21 | $449 | $21 |
| Econazole Nitrate | 11 | $421 | $38 |
| Gabapentin | 14 | $277 | $20 |
Money from drug and device companies
$137,987 in 2025
| 2025 | 4 | 77 | $130,708 | $137,987 |
| 2024 | 3 | 77 | $92,930 | $101,071 |
| 2023 | 4 | 77 | $85,545 | $98,492 |
| 2022 | 4 | 50 | $56,048 | $59,062 |
| 2021 | 1 | 33 | $36,250 | $38,181 |
| 2019 | 2 | 11 | $5,600 | $6,969 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Galderma Laboratories L.P. | Nemluvio | $52,775 | 27 payments
|
| Regeneron Healthcare Solutions | Dupixent | $47,624 | 28 payments
|
| Abbvie | Skyrizi | $31,454 | 19 payments
|
| Genzyme | Dupixent | $6,134 | 3 payments
|
See all 77 published payments
| Galderma Laboratories L.P. | Meals · 2025-11-20 | Nemluvio | $100 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-11-14 | Nemluvio | $5,400 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-11-14 | Nemluvio | $2,250 |
| Abbvie | Paid to speak or teach · 2025-11-12 | Rinvoq | $2,875 |
| Abbvie | Paid to speak or teach · 2025-11-07 | Skyrizi | $2,875 |
| Galderma Laboratories L.P. | Meals · 2025-11-04 | Nemluvio | $30 |
| Abbvie | Meals · 2025-10-27 | Skyrizi | $26 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-10-24 | Dupixent | $1,670 |
| Abbvie | Meals · 2025-10-21 | Rinvoq | $128 |
| Regeneron Healthcare Solutions | Travel · 2025-10-21 | Dupixent | $134 |
| Regeneron Healthcare Solutions | Travel · 2025-10-21 | Dupixent | $48 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-09-26 | Nemluvio | $3,600 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-09-23 | Dupixent | $8,350 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-09-19 | Nemluvio | $2,250 |
| Regeneron Healthcare Solutions | Meals · 2025-09-18 | Dupixent | $125 |
| Regeneron Healthcare Solutions | Travel · 2025-09-16 | Dupixent | $56 |
| Regeneron Healthcare Solutions | Travel · 2025-09-16 | Dupixent | $65 |
| Galderma Laboratories L.P. | Meals · 2025-09-16 | Nemluvio | $150 |
| Regeneron Healthcare Solutions | Travel · 2025-09-15 | Dupixent | $269 |
| Regeneron Healthcare Solutions | Travel · 2025-09-10 | Dupixent | $417 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-08-29 | None | $3,600 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-08-22 | Dupixent | $4,342 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-08-22 | Nemluvio | $3,600 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-08-20 | Nemluvio | $600 |
| Galderma Laboratories L.P. | Meals · 2025-08-19 | None | $170 |
| Regeneron Healthcare Solutions | Travel · 2025-08-14 | Dupixent | $259 |
| Genzyme | Paid to speak or teach · 2025-08-06 | Dupixent | $2,338 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-07-25 | Dupixent | $1,169 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-07-22 | Dupixent | $3,674 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-07-18 | Nemluvio | $1,800 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-07-11 | Dupixent | $3,006 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-07-01 | Dupixent | $8,350 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-06-27 | Dupixent | $2,839 |
| Regeneron Healthcare Solutions | Travel · 2025-06-26 | Dupixent | $269 |
| Regeneron Healthcare Solutions | Travel · 2025-06-26 | Dupixent | $256 |
| Regeneron Healthcare Solutions | Travel · 2025-06-25 | Dupixent | $142 |
| Regeneron Healthcare Solutions | Meals · 2025-06-25 | Dupixent | $121 |
| Regeneron Healthcare Solutions | Meals · 2025-06-25 | Dupixent | $37 |
| Abbvie | Paid to speak or teach · 2025-06-24 | Skyrizi | $4,025 |
| Regeneron Healthcare Solutions | Travel · 2025-06-19 | Dupixent | $647 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-06-06 | Nemluvio | $3,600 |
| Abbvie | Paid to speak or teach · 2025-05-30 | Skyrizi | $2,875 |
| Galderma Laboratories L.P. | Meals · 2025-05-27 | Nemluvio | $129 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-05-12 | Nemluvio | $9,300 |
| Abbvie | Meals · 2025-05-09 | Skyrizi | $52 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-05-06 | Dupixent | $4,342 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-05-02 | None | $5,678 |
| Regeneron Healthcare Solutions | Meals · 2025-05-02 | Dupixent | $117 |
| Galderma Laboratories L.P. | Meals · 2025-04-30 | Nemluvio | $106 |
| Galderma Laboratories L.P. | Travel · 2025-04-30 | Nemluvio | $46 |
| Galderma Laboratories L.P. | Travel · 2025-04-30 | Nemluvio | $327 |
| Regeneron Healthcare Solutions | Travel · 2025-04-29 | None | $735 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-04-18 | Nemluvio | $3,600 |
| Regeneron Healthcare Solutions | Education · 2025-04-14 | Dupixent | $7 |
| Abbvie | Paid to speak or teach · 2025-04-11 | Rinvoq | $1,725 |
| Abbvie | Travel · 2025-04-10 | Skyrizi | $860 |
| Abbvie | Travel · 2025-04-10 | Skyrizi | $200 |
| Abbvie | Meals · 2025-04-10 | Skyrizi | $56 |
| Galderma Laboratories L.P. | Meals · 2025-04-09 | Nemluvio | $29 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-04-04 | Nemluvio | $5,400 |
| Galderma Laboratories L.P. | Meals · 2025-03-27 | Nemluvio | $107 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-03-21 | None | $501 |
| Abbvie | Paid to speak or teach · 2025-02-21 | Rinvoq | $4,025 |
| Abbvie | Travel · 2025-02-14 | Rinvoq | $192 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-02-14 | Nemluvio | $3,600 |
| Genzyme | Meals · 2025-02-10 | Dupixent | $122 |
| Genzyme | Paid to speak or teach · 2025-02-10 | Dupixent | $3,674 |
| Galderma Laboratories L.P. | Meals · 2025-02-07 | Nemluvio | $98 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-02-05 | Nemluvio | $2,250 |
| Galderma Laboratories L.P. | Meals · 2025-01-30 | Nemluvio | $33 |
| Abbvie | Travel · 2025-01-28 | Skyrizi | $446 |
| Abbvie | Meals · 2025-01-23 | Rinvoq | $125 |
| Galderma Laboratories L.P. | Paid to speak or teach · 2025-01-15 | Nemluvio | $600 |
| Abbvie | Travel · 2025-01-09 | Skyrizi | $44 |
| Abbvie | Paid to speak or teach · 2025-01-09 | Skyrizi | $4,025 |
| Abbvie | Paid to speak or teach · 2025-01-09 | Skyrizi | $2,875 |
| Abbvie | Paid to speak or teach · 2025-01-09 | Skyrizi | $4,025 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $101,071
| Abbvie | Skyrizi | $69,799 | 55 payments
|
| Regeneron Healthcare Solutions | Dupixent | $22,248 | 10 payments
|
| Galderma Laboratories L.P. | None | $9,024 | 12 payments
|
2023: $98,492
| Regeneron Healthcare Solutions | Dupixent | $51,256 | 39 payments
|
| Abbvie | Skyrizi | $42,736 | 33 payments
|
| Genzyme | Dupixent | $4,470 | 3 payments
|
| Pfizer | Cibinqo | $31 | 2 payments
|
2022: $59,062
| Abbvie | Skyrizi | $46,476 | 40 payments
|
| Pfizer | Cibinqo | $5,738 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $5,668 | 5 payments
|
| Ucb | None | $1,180 | 1 payment
|
2021: $38,181
| AbbVie | Skyrizi | $38,181 | 33 payments
|
2019: $6,969
| AbbVie | Humira | $4,869 | 10 payments
|
| Gilead Sciences | None | $2,100 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1235454182
- Licence
- CA A131557California A131557: Current · expires 2028-07-31
- Trained
- George Washington University School of Medicine, 2009
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 440 Broadway St Fl B4, Redwood City, CA, 94063
- NPI first listed
- 2010-04-05
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 440 Broadway St Fl B4, Redwood City, CA, 94063